Discover 180 paid clinical trials in Fargo, North Dakota. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 180
Active & Responsive
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma
Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis
for
Atopic Dermatitis (AD), Psoriasis (PsO)
Location: Fargo ND, Dallas TX
Sponsor: LAPIX Therapeutics Inc.
Sex: All
Age: 18+
Code: NCT06982352
Phase1, Recruiting
Active & Responsive
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Get alerts for new trials in your area by subscribing now
Active & Responsive
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
for
Diabetes Mellitus, Type 2, PreDiabetes, Metabolic Syndrome
Location: Fargo ND, Minneapolis MN, West Des Moines IA,
Sponsor: Cleerly, Inc.
Sex: All
Age: 55+
Code: NCT06112418
Recruiting
Active & Responsive
Opioids Versus Non-Opioids Postoperative After Knee Arthroscopic Surgery
for
Knee Injuries, Pain, Postoperative, Opioid Use
Location: Fargo ND
Sponsor: Sanford Health
Sex: All
Age: 18 - 70+
Code: NCT03858231
Recruiting
Active & Responsive
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
for
Non-small Cell Lung Cancer (NSCLC)
Location: Fargo ND, Sioux Falls SD, Springfield MO, Ann Arbor MI,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06305754
Phase3, Recruiting
Active & Responsive
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)